Back to search results

Dietary and Topical Magnesium for Lymphoma Patients

This study is looking at whether eating magnesium-rich foods and using a Magnesium Chloride-based Lotion on your skin can help keep magnesium levels in your blood healthy if you have lymphoma. Magnesium is important for your body's cells, but your body can't make it on its own. Often, people who are sick get magnesium through an IV (into a vein) or by mouth. This early study wants to see if these methods work well to keep your magnesium levels in a good range. Researchers will also check for any side effects and how these methods affect your quality of life. You can join if you are 18 or older and have been diagnosed with any type of lymphoma. The main goal is to see if your magnesium blood levels improve over about 2 months (56 days). The study plans to enroll 60 participants.

Study design
This is an interventional study, meaning participants will receive specific treatments. It plans to enroll 60 participants.
What's involved
Participants will consume magnesium-rich foods daily for 28 days. Depending on their magnesium levels after this, some may also use a topical Magnesium Chloride-based Lotion.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, improvement in serum magnesium levels, is measured up to 2 cycles (56 days).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05294367

Dietary and Topical Magnesium Replacement or Supplementation in Patients With Lymphoma

Recruiting
EARLY_PHASE1Ages 18+InterventionalTreatment
Mayo Clinic
~60 participants
Updated 2026-03-16 on ClinicalTrials.gov
What's tested:Magnesium Chloride-based LotionQuality-of-Life AssessmentSpecial Diet Therapy

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Improvement in serum magnesium levels
Measured over Baseline up to 2 cycles (56 days)

Conditions

Lymphoma

Explore related trials

Lymphoma

NCT05294367

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Mayo Clinic in Rochester

    Rochester, Minnesotastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Thomas E. Witzig, M.D. · PRINCIPAL_INVESTIGATOR · Mayo Clinic in Rochester

Who to contact

Clinical Trials Referral Office
[email protected]
855-776-0015
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age \>= 18 years
Currently have or have had in the past the diagnosis of any type of lymphoma
If previously treated, the patient must be off myelosuppressive chemotherapy with no planned chemotherapy for \>= 2 months. Patients with lymphoproliferative disorders being observed (i.e., never treated) or those on rituximab (or equivalent) maintenance or chronic oral therapies such as BTK inhibitors, venetoclax, tazemetostat, or corticosteroids are also eligible
Able to eat a full range of solid food and liquids and tolerate seeds/nuts
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0, 1, or 2
Provide written informed consent
Able to recollect dietary intake for the prior 24 hours in order to complete a one-day food record with assistance from a dietitian at each study visit
Willing to be seen at the enrolling institution at baseline, and at 4 weeks and 8 weeks (end of treatment) in person or by video/phone
Willing to have a blood magnesium checked every 2 weeks x 4 at any Mayo Clinic site
Ability to complete questionnaire(s) by themselves or with assistance
Magnesium level of 1.5 - 1.9 mg/dL (obtained =\< 5 days prior to registration)

Exclusion

Cannot eat normal table food by mouth. NOTE: Patients with any form of feeding tube or a swallowing disorder are not eligible
Have taken dedicated magnesium supplements (i.e. magnesium oxide) or intravenous (IV) magnesium =\< 28 days prior to pre-registration. Note: If patient is already on a multivitamin containing -magnesium, they may be enrolled, but the brand should not be changed during the 8 weeks on study
Co-morbid systemic illnesses such as active infection or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
Patients with significant gut malabsorptive conditions (such as inflammatory bowel disease or others at the discretion of the investigator) will be excluded as well as patients with chronic kidney disease stage 3b or greater (estimated glomerular filtration rate \[eGFR\] \< 45)
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Receiving any other investigational agent for lymphoma or any other disease
Active other malignancy requiring treatment that would interfere with the assessments of this study
Major surgery other than diagnostic surgery =\< 4 weeks prior to pre-registration
Have an allergy to nuts
Patients with active skin lymphoma or rashes that would preclude lotion testing
Have taken antibiotics =\< 7 days prior to pre-registration

What this trial measures

  • Improvement in serum magnesium levelsBaseline up to 2 cycles (56 days)

    Will be defined as an increase in magnesium levels of at least 0.2 mg/dL from baseline level or an increase in magnesium level to 2.0 - 2.3 mg/dL at any time after the beginning of replacement.